Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26601369 | 0.83 | AKR1C3 (0.49) | NOTUMPOLBALDH1A1PKMMAPT | |
| SCHEMBL9292198 | 0.82 | HSP90AA1 (0.49) | NOTUMMEN1KMT2AALKBH5ALDH1A1 | |
| SCHEMBL1137068 | 0.82 | KDM4E (0.54) | NOTUMMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL4137779 | 0.78 | NOTUM (0.53) | NOTUMMEN1KMT2AALKBH5POLB | |
| SCHEMBL4313192 | 0.78 | ALDH1A1 (0.42) | NOTUMMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL1259232 | 0.76 | ALDH1A1 (0.49) | NOTUMMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL4430908 | 0.76 | ALDH1A1 (0.51) | MEN1KMT2APOLBALDH1A1MAPT | |
| SCHEMBL1260210 | 0.76 | NOTUM (0.64) | NOTUMMEN1KMT2AALKBH5POLB | |
| SCHEMBL2676151 | 0.75 | KDM4E (0.73) | NOTUMMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL25529181 | 0.75 | KDM4E (0.40) | MEN1KMT2APOLBALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562902-B1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2006-05-03 | — | — | EP | disclosed |
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | ASRAZENECA AB (SE) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | SERPINB1, ELANE, SERPINE1 | NOTUM 3748/4885MEN1 3423/4885KMT2A 4487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.